CRMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
CorMedix Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$7.38+0.12 (+1.65%)
Close on Oct 19, 2026
- Market cap
- $682.50M
- P/E (TTM)
- 3.6
- Dividend yield
- –
CorMedix statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | CorMedix | Industry median |
|---|---|---|
| Market Cap | $575.23M | $164.85M |
| Enterprise Value | $318.54M | $87.06M |
| PS Ratio | 1.24 | 3.60 |
| PB Ratio | 1.25 | 2.03 |
| P/TBV Ratio | 7.95 | 2.31 |
| P/FCF Ratio | 2.30 | 17.44 |
| P/OCF Ratio | 2.27 | 13.32 |
Enterprise value
| Measure | CorMedix | Industry median |
|---|---|---|
| EV / Sales | 0.69 | 2.43 |
| EV / EBITDA | 1.47 | 14.69 |
| EV / EBIT | 1.47 | 18.47 |
| EV / FCF | 1.27 | 20.97 |
Income (trailing twelve months)
| Measure | CorMedix | Industry median |
|---|---|---|
| Revenue | $462.25M | $57.94M |
| Gross Profit | $382.64M | $90.47M |
| Operating Income | $217.04M | -$21.44M |
| Pretax Income | $203.40M | -$14.45M |
| Net Income | $187.17M | -$22.46M |
| EBITDA | $217.04M | -$16.91M |
Margins
| Measure | CorMedix | Industry median |
|---|---|---|
| Gross Margin | 82.8% | 52.3% |
| Operating Margin | 47.0% | -44.5% |
| Pretax Margin | 44.0% | -13.0% |
| Profit Margin | 40.5% | -39.2% |
| EBITDA Margin | 47.0% | -31.3% |
| FCF Margin | 54.2% | -8.85% |
Returns
| Measure | CorMedix | Industry median |
|---|---|---|
| Return on Equity (ROE) | 54.9% | -53.1% |
| Return on Assets (ROA) | 32.4% | -41.0% |
| Return on Invested Capital (ROIC) | 170.7% | -32.0% |
| Return on Capital Employed (ROCE) | 30.3% | -37.8% |
Growth
| Measure | CorMedix | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 280.5% | 6.01% |
| Net Income Growth (YoY) | 265.9% | -37.7% |
| FCF Growth (YoY) | 723.5% | 2.34% |
| Revenue Growth (3Y CAGR) | 1582.8% | 2.25% |
| Revenue Growth (5Y CAGR) | 319.7% | 6.42% |
Balance sheet
| Measure | CorMedix | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $256.69M | $62.42M |
| Net Cash (Debt) | $256.69M | $15.68M |
| Net Cash Per Share | $3.29 | $0.66 |
| Equity (Book Value) | $460.83M | $48.79M |
| Book Value Per Share | $5.91 | $1.36 |
| Tangible Book Value | $72.36M | $23.06M |
| Working Capital | $293.16M | $75.77M |
Financial position
| Measure | CorMedix | Industry median |
|---|---|---|
| Current Ratio | 2.56 | 3.30 |
| Quick Ratio | 2.23 | 2.39 |
Cash flow (trailing twelve months)
| Measure | CorMedix | Industry median |
|---|---|---|
| Operating Cash Flow | $253.94M | -$12.35M |
| Capital Expenditures | -$3.52M | -$1.06M |
| Free Cash Flow | $250.42M | -$20.28M |
| FCF Per Share | $3.21 | -$0.42 |
Efficiency
| Measure | CorMedix | Industry median |
|---|---|---|
| Asset Turnover | 0.80 | 0.38 |
| Inventory Turnover | 1.88 | 2.67 |
| Revenue Per Employee | $2.42M | $398.96K |
| Profits Per Employee | $979.96K | -$703.34K |
| Employee Count | 191 | 74 |
Dividends and yields
| Measure | CorMedix | Industry median |
|---|---|---|
| Earnings Yield | 32.5% | -22.7% |
| FCF Yield | 43.5% | -9.07% |
| Buyback Yield | -0.18% | -0.73% |
| Shareholder Yield | -0.18% | 0.00% |
Shares
| Measure | CorMedix | Industry median |
|---|---|---|
| Shares Outstanding | 77,944,300 | 58,179,650 |
| Shares Change (QoQ) | -0.93% | 0.54% |
| Float | 75,471,300 | 49,173,100 |
| Shares Held by Insiders | 3.17% | 11.6% |
| Shares Held by Institutions | 56.5% | 59.4% |
Taxes
| Measure | CorMedix | Industry median |
|---|---|---|
| Income Tax | $16.23M | $91.50K |
| Effective Tax Rate | 7.98% | 20.6% |
Scores
| Measure | CorMedix | Industry median |
|---|---|---|
| Altman Z-Score | 2.30 | -0.24 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from CorMedix's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.